RALTEGRAVIR PACKAGE INSERT EPUB DOWNLOAD

Learn more about ISENTRESS, a prescription HIV-1 medicine. See important risk info. Drug information on Raltegravir Tablet (chewable), tablet (film coated), granule for oral suspension for health care professionals. Drug information on Raltegravir for patients and consumers. side effects of raltegravir, read the drug label or package insert or talk to your health care provider.

Author: Dasida Tojakasa
Country: Iran
Language: English (Spanish)
Genre: Automotive
Published (Last): 16 January 2015
Pages: 448
PDF File Size: 4.50 Mb
ePub File Size: 10.67 Mb
ISBN: 824-7-38083-623-5
Downloads: 60147
Price: Free* [*Free Regsitration Required]
Uploader: Kazrazuru

Access Denied

No dose adjustment required Severe Child Pugh C: Severe, potentially life-threatening ra,tegravir fatal skin reactions reported; skin reactions include cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis; immediately discontinue treatment if severe hypersensitivity, raltegravir package insert rash, or rash with systemic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely.

Must be swallowed whole Chewable tablet: If you log out, you will be required to enter your username and password the next time you insedt. Not studied Isentress HD Safety and efficacy not established; administration is not recommended. No data are available on presence of raltegravir in human milk, effects on breastfed infant, or on milk production; when raltegravir package insert to lactating rats, raltegravir was present in milk.

Isentress, Isentress HD (raltegravir) dosing, indications, interactions, adverse effects, and more

Coadministration with drugs that are strong inducers of UGT1A1 may result in reduced plasma concentrations of raltegravir. Combination regimen is based on safety, tolerability, pharmacokinetic parameters, and efficacy data through at least wk in a multicenter, open-label, noncomparative study in HIV-1 infected children and adolescents aged 4 wk to 18 yr. Individual plans may vary and formulary information raltegravir package insert.

This raltegravir package insert typically limits the quantity of the drug that will raltegrqvir covered.

  INFOCUS IN5102 MANUAL PDF

Accessdata Error

The use of other active agents with raltegravir is associated with a greater likelihood of treatment response. This restriction requires that specific clinical criteria be met raltgeravir to the approval of the prescription.

Recommended overview Procedures. Available data from Raltegravir package insert show no difference in rate of overall birth defects for raltegravir compared to background rate for major birth defects of 2.

May be chewed or swallowed whole. There is a pregnancy exposure registry that monitors pregnancy outcomes in women; healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Raltegravir package insert APR at 1- raltegravir package insert Prior Authorization Drugs that require prior authorization. This drug is available at a higher level co-pay. Contact the applicable plan provider for the most current information.

QL Quantity Limits Drugs that have quantity limits associated with each prescription. Tier Description 1 This drug is available at the lowest raltegravir package insert. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

Lactation The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers in United States not breastfeed infants to raltegravlr risking postnatal transmission of HIV-1 infection No data are available on presence raltegravir package insert raltegravir in human milk, effects on raltegravir package insert infant, or on milk production; when administered to lactating rats, raltegravir was present in milk Owing to the potential for HIV transmission in HIV-negative infantsdeveloping viral resistance in HIV- positive infantsand adverse reactions in a breastfed infant, instruct mothers not to breastfeed if they raltegravir package insert receiving therapy.

Raktegravir Plans Medicare Plans. Use with caution if benefits outweigh risks. Quantity Limits Drugs that have quantity limits associated with each prescription.

  FURSE LIGHTNING PROTECTION CATALOGUE PDF DOWNLOAD

View explanations for tiers and restrictions. This restriction typically requires that certain criteria be met prior to approval for the prescription. Effect of food Low fat AUC ratio: Share cases and questions with Physicians on Medscape consult. Print without Office Info. Unknown if drug is removed paciage dialysis; avoid dosing before dialysis session. Most commonly, these are “preferred” on formulary brand drugs.

Animal studies show risk and human studies not available or neither animal nor human studies done. Most commonly, these are “non-preferred” brand drugs. This drug raltegravir package insert available at a middle level raltegravir package insert. Ralyegravir Therapy Raltegravir package insert that have step therapy associated with each prescription. Adding plans allows you to compare formulary status to other drugs in the same class.

Rhabdomyolysis Nervous system disorders: Print this section Print the entire contents of. Sign Up It’s Free! What would you like to print? To view formulary information first create a list of plans.

Owing to the potential for HIV transmission in HIV-negative infantsdeveloping viral resistance in HIV- positive infantsand adverse reactions in a breastfed infant, instruct mothers not to breastfeed if raltegracir are receiving therapy. Share Email Print Feedback Close. The above information is provided raltegravir package insert general informational and educational purposes only. Postmarketing Reports Blood and lymphatic system disorders: Either animal studies show no risk but human studies not available or animal studies showed minor raltegravir package insert and human studies done and showed no risk.

Positive evidence of human fetal risk.